Weber DM - Search Results

1

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.

Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Hunsucker SA, et al. Among authors: weber dm. Br J Haematol. 2011 Mar;152(5):579-92. doi: 10.1111/j.1365-2141.2010.08533.x. Epub 2011 Jan 17. Br J Haematol. 2011. PMID: 21241278 Free PMC article.

2

Prognostic features of asymptomatic multiple myeloma.

Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Weber DM, et al. Br J Haematol. 1997 Jun;97(4):810-4. doi: 10.1046/j.1365-2141.1997.1122939.x. Br J Haematol. 1997. PMID: 9217181 Free article.

3

Newly diagnosed multiple myeloma.

Weber DM. Weber DM. Curr Treat Options Oncol. 2002 Jun;3(3):235-45. doi: 10.1007/s11864-002-0013-4. Curr Treat Options Oncol. 2002. PMID: 12057069 Review.

4

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.

Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Weber D, et al. J Clin Oncol. 2003 Jan 1;21(1):16-9. doi: 10.1200/JCO.2003.03.139. J Clin Oncol. 2003. PMID: 12506164 Clinical Trial.

5

Thalidomide and dexamethasone for resistant multiple myeloma.

Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Anagnostopoulos A, et al. Br J Haematol. 2003 Jun;121(5):768-71. doi: 10.1046/j.1365-2141.2003.04345.x. Br J Haematol. 2003. PMID: 12780791 Free article.

6

Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma.

Ahmed M, Giles F, Joe Y, Weber DM, Jilani I, Manshouri T, Giralt S, De Lima M, Keating M, Albitar M. Ahmed M, et al. Among authors: weber dm. Eur J Haematol. 2003 Sep;71(3):174-8. doi: 10.1034/j.1600-0609.2003.00125.x. Eur J Haematol. 2003. PMID: 12930317

7

Thalidomide and its derivatives: new promise for multiple myeloma.

Weber D. Weber D. Cancer Control. 2003 Sep-Oct;10(5):375-83. doi: 10.1177/107327480301000504. Cancer Control. 2003. PMID: 14581892 Free article. Review.

8

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Alexanian R, et al. Semin Hematol. 2003 Oct;40(4 Suppl 4):3-7. doi: 10.1053/j.seminhematol.2003.09.006. Semin Hematol. 2003. PMID: 15015890 Review.

9

High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.

Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, de Lima M, Anagnostopoulos A, Giralt S. Donato ML, et al. Leuk Lymphoma. 2004 Apr;45(4):755-9. doi: 10.1080/10428190310001603957. Leuk Lymphoma. 2004. PMID: 15160952 Clinical Trial.

10

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.

Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S. Anagnostopoulos A, et al. Cancer. 2004 Jun 15;100(12):2607-12. doi: 10.1002/cncr.20294. Cancer. 2004. PMID: 15197803 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

249 results

Search Page

Filters